PGR and breast carcinoma: Although patient accrual in this study was small (19 patients), 67% of patients achieved tumor remission when treated with onapristone, a PR type I antagonist that blocks PR binding to DNA, as front-line endocrine therapy for locally advanced or primary breast cancer [42].